Scholar Rock Holding Corporation (SRRK) is a Healthcare stock trading at $47.30 (as of 2026-06-18), with a market capitalization of $5.91B and a trailing P/E of -14.3. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.
Scholar Rock Holding Corporation is a biopharmaceutical company developing therapies that target protein growth-factor signaling. Its programs include apitegromab for spinal muscular atrophy (Phase 3) and SRK-181 for certain cancers resistant to checkpoint inhibitor antibodies (Phase 1), alongside a pipeline spanning neuromuscular disorders, cancer, and fibrosis, including collaboration with Gilead Sciences on inhibitors of TGF-beta activation.